Skip to content
Company Analysis

Haemonetics Corporation HAE

A comprehensive view of key metrics, scores, and financial health for Haemonetics Corporation

Overview of Haemonetics Corporation

HAE NYQ
Healthcare Medical Instruments & Supplies Framework: Medical Devices & Diagnostics Mid Cap
Haemonetics Corporation (HAE), is a Mid Cap company, in the Medical Instruments & Supplies industry, last closed at $78.20, about 36.0% overvalued vs fair value, +11.6% 1Y return, placing in the top 10% of its sector.
Metrics P/E 19.2× Rev Growth 4.0% ROE 18.8% Gross Margin 55.0%
USD 78.20
-2.05%
(Delayed)
• Vol 90d: 41.5%
52-Week Range
Market Cap
$3.58B
Enterprise Value
$4.44B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Good
Health
Good
Efficiency
Good
Valuation
Fair
Growth
Good
Profitability
Good
Health
Good
Efficiency
Good
Valuation
Fair
Completeness: 82%
Confidence: 79%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.haemonetics.com
HQ Boston, MA
Employees 3,023
Fiscal year Mar 31

Next Events

Earnings Aug 6 Estimated

Fair Value Snapshot

Bear Base Bull
$44
$50
$56
Current: $78.20 -36% vs base

Engine Room Money Flow™

Mid Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$1.4B
4%%
Gross Profit
$749.0M
8.3%%
Operating Income (GAAP)
$201.2M
16.1%%
EBITDA
$337.4M
28.7%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
55.0%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
0
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Haemonetics Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
67
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
57
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing HAE's balance between Growth (29.8%), Profitability (34.5%), and Safety (35.7%). Growth 30% Safety 36% Profitability 34%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

63th percentile vs peers
63
Key Signals
EPS CAGR 3Y 57.6% 94p Rev Growth YoY 4.0% 43p EPS Growth YoY 44.5% 65p Revenue CAGR 3Y 11.1% 59p TSR 31.1% 69p
Strengths
  • EPS CAGR 3Y in top 20% of peers (57.6%, 94th percentile)
  • Operating Margin in top 20% of peers (14.8%, 83th percentile)
  • Interest Coverage (EBITDA) in top 20% of peers (34.62, 90th percentile)
  • D/E Ratio in top 20% of peers (1.49, 88th percentile)
  • Cash Flow to Debt Ratio in top 20% of peers (1.31, 84th percentile)
Risks

No significant risks identified for this axis.

Profitability

73th percentile vs peers
73
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

75th percentile vs peers
76
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Haemonetics Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$50.06
- - -
-36.0% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000